ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared ...
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT ...
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and self-amplifying messenger RNA (sa-mRNA) pioneer Arcturus ...
biopharma-reporter1d
Self-amplifying mRNA COVID-19 vaccine shows superiority over conventional mRNA vaccine
A head-to-head study has revealed that CSL and Arcturus Therapeutic’s self-amplifying mRNA vaccine can maintain a stronger ...
24/7 Wall St2d
Arcturus Therapeutics Holdings Inc
The company's pipeline includes ARCT-810, a treatment for ornithine transcarbamylase deficiency in Phase 2 trials, ARCT-154, a COVID-19 vaccine candidate in Phase 3 trials in Vietnam, and ARCT-032 ...